Memantine inhibits cortical spreading depolarization and improves neurovascular function following repetitive traumatic brain injury

Cortical spreading depolarization (CSD) is a promising target for neuroprotective therapy in traumatic brain injury (TBI). We explored the effect of NMDA receptor antagonism on electrically triggered CSDs in healthy and brain-injured animals. Rats received either one moderate or four daily repetitiv...

Full description

Saved in:
Bibliographic Details
Published inScience advances Vol. 9; no. 50; p. eadj2417
Main Authors MacLean, Mark A., Muradov, Jamil H., Greene, Ryan, Van Hameren, Gerben, Clarke, David B., Dreier, Jens P., Okonkwo, David O., Friedman, Alon
Format Journal Article
LanguageEnglish
Published United States American Association for the Advancement of Science 15.12.2023
Subjects
Animals
Brain - metabolism
Brain Injuries, Traumatic - drug therapy
Electrocorticography
Memantine - pharmacology
Neuroscience
Rats
Receptors, N-Methyl-D-Aspartate - metabolism
SciAdv r-articles
Online AccessGet full text

Cover

Abstract Cortical spreading depolarization (CSD) is a promising target for neuroprotective therapy in traumatic brain injury (TBI). We explored the effect of NMDA receptor antagonism on electrically triggered CSDs in healthy and brain-injured animals. Rats received either one moderate or four daily repetitive mild closed head impacts (rmTBI). Ninety-three animals underwent craniectomy with electrocorticographic (ECoG) and local blood flow monitoring. In brain-injured animals, ketamine or memantine inhibited CSDs in 44 to 88% and 50 to 67% of cases, respectively. Near-DC/AC-ECoG amplitude was reduced by 44 to 75% and 52 to 67%, and duration by 39 to 87% and 61 to 78%, respectively. Daily memantine significantly reduced spreading depression and oligemia following CSD. Animals ( N = 31) were randomized to either memantine (10 mg/kg) or saline with daily neurobehavioral testing. Memantine-treated animals had higher neurological scores. We demonstrate that memantine improved neurovascular function following CSD in sham and brain-injured animals. Memantine also prevented neurological decline in a blinded, preclinical randomized rmTBI trial. Memantine inhibited cortical spreading depolarization and prevented neurobehavioral decline following traumatic brain injury.
AbstractList Cortical spreading depolarization (CSD) is a promising target for neuroprotective therapy in traumatic brain injury (TBI). We explored the effect of NMDA receptor antagonism on electrically triggered CSDs in healthy and brain-injured animals. Rats received either one moderate or four daily repetitive mild closed head impacts (rmTBI). Ninety-three animals underwent craniectomy with electrocorticographic (ECoG) and local blood flow monitoring. In brain-injured animals, ketamine or memantine inhibited CSDs in 44 to 88% and 50 to 67% of cases, respectively. Near-DC/AC-ECoG amplitude was reduced by 44 to 75% and 52 to 67%, and duration by 39 to 87% and 61 to 78%, respectively. Daily memantine significantly reduced spreading depression and oligemia following CSD. Animals (N = 31) were randomized to either memantine (10 mg/kg) or saline with daily neurobehavioral testing. Memantine-treated animals had higher neurological scores. We demonstrate that memantine improved neurovascular function following CSD in sham and brain-injured animals. Memantine also prevented neurological decline in a blinded, preclinical randomized rmTBI trial.Cortical spreading depolarization (CSD) is a promising target for neuroprotective therapy in traumatic brain injury (TBI). We explored the effect of NMDA receptor antagonism on electrically triggered CSDs in healthy and brain-injured animals. Rats received either one moderate or four daily repetitive mild closed head impacts (rmTBI). Ninety-three animals underwent craniectomy with electrocorticographic (ECoG) and local blood flow monitoring. In brain-injured animals, ketamine or memantine inhibited CSDs in 44 to 88% and 50 to 67% of cases, respectively. Near-DC/AC-ECoG amplitude was reduced by 44 to 75% and 52 to 67%, and duration by 39 to 87% and 61 to 78%, respectively. Daily memantine significantly reduced spreading depression and oligemia following CSD. Animals (N = 31) were randomized to either memantine (10 mg/kg) or saline with daily neurobehavioral testing. Memantine-treated animals had higher neurological scores. We demonstrate that memantine improved neurovascular function following CSD in sham and brain-injured animals. Memantine also prevented neurological decline in a blinded, preclinical randomized rmTBI trial.
Cortical spreading depolarization (CSD) is a promising target for neuroprotective therapy in traumatic brain injury (TBI). We explored the effect of NMDA receptor antagonism on electrically triggered CSDs in healthy and brain-injured animals. Rats received either one moderate or four daily repetitive mild closed head impacts (rmTBI). Ninety-three animals underwent craniectomy with electrocorticographic (ECoG) and local blood flow monitoring. In brain-injured animals, ketamine or memantine inhibited CSDs in 44 to 88% and 50 to 67% of cases, respectively. Near-DC/AC-ECoG amplitude was reduced by 44 to 75% and 52 to 67%, and duration by 39 to 87% and 61 to 78%, respectively. Daily memantine significantly reduced spreading depression and oligemia following CSD. Animals ( N = 31) were randomized to either memantine (10 mg/kg) or saline with daily neurobehavioral testing. Memantine-treated animals had higher neurological scores. We demonstrate that memantine improved neurovascular function following CSD in sham and brain-injured animals. Memantine also prevented neurological decline in a blinded, preclinical randomized rmTBI trial. Memantine inhibited cortical spreading depolarization and prevented neurobehavioral decline following traumatic brain injury.
Cortical spreading depolarization (CSD) is a promising target for neuroprotective therapy in traumatic brain injury (TBI). We explored the effect of NMDA receptor antagonism on electrically triggered CSDs in healthy and brain-injured animals. Rats received either one moderate or four daily repetitive mild closed head impacts (rmTBI). Ninety-three animals underwent craniectomy with electrocorticographic (ECoG) and local blood flow monitoring. In brain-injured animals, ketamine or memantine inhibited CSDs in 44 to 88% and 50 to 67% of cases, respectively. Near-DC/AC-ECoG amplitude was reduced by 44 to 75% and 52 to 67%, and duration by 39 to 87% and 61 to 78%, respectively. Daily memantine significantly reduced spreading depression and oligemia following CSD. Animals ( = 31) were randomized to either memantine (10 mg/kg) or saline with daily neurobehavioral testing. Memantine-treated animals had higher neurological scores. We demonstrate that memantine improved neurovascular function following CSD in sham and brain-injured animals. Memantine also prevented neurological decline in a blinded, preclinical randomized rmTBI trial.
Author Dreier, Jens P.
Greene, Ryan
Friedman, Alon
Van Hameren, Gerben
Clarke, David B.
MacLean, Mark A.
Okonkwo, David O.
Muradov, Jamil H.
Author_xml – sequence: 1
  givenname: Mark A.
  orcidid: 0000-0002-8535-0776
  surname: MacLean
  fullname: MacLean, Mark A.
  organization: Division of Neurosurgery, Dalhousie University, Halifax, Canada
– sequence: 2
  givenname: Jamil H.
  orcidid: 0009-0005-3437-5067
  surname: Muradov
  fullname: Muradov, Jamil H.
  organization: Department of Medical Neuroscience, Dalhousie University, Halifax, Canada
– sequence: 3
  givenname: Ryan
  orcidid: 0000-0002-8211-7450
  surname: Greene
  fullname: Greene, Ryan
  organization: Department of Medical Neuroscience, Dalhousie University, Halifax, Canada
– sequence: 4
  givenname: Gerben
  surname: Van Hameren
  fullname: Van Hameren, Gerben
  organization: Department of Medical Neuroscience, Dalhousie University, Halifax, Canada
– sequence: 5
  givenname: David B.
  orcidid: 0000-0003-3816-6674
  surname: Clarke
  fullname: Clarke, David B.
  organization: Division of Neurosurgery, Dalhousie University, Halifax, Canada
– sequence: 6
  givenname: Jens P.
  orcidid: 0000-0001-7459-2828
  surname: Dreier
  fullname: Dreier, Jens P.
  organization: Center for Stroke Research Berlin, Charite University, Berlin, Germany
– sequence: 7
  givenname: David O.
  orcidid: 0000-0002-7444-2851
  surname: Okonkwo
  fullname: Okonkwo, David O.
  organization: Division of Neurosurgery, University of Pittsburgh, Pittsburgh, PA, USA
– sequence: 8
  givenname: Alon
  orcidid: 0000-0003-4780-8456
  surname: Friedman
  fullname: Friedman, Alon
  organization: Division of Neurosurgery, Dalhousie University, Halifax, Canada., Department of Medical Neuroscience, Dalhousie University, Halifax, Canada., Departments of Brain and Cognitive Sciences, Physiology and Cell Biology, Ben-Gurion University of the Negev, Beer-Sheva, Israel
BackLink https://www.ncbi.nlm.nih.gov/pubmed/38091390$$D View this record in MEDLINE/PubMed
BookMark eNp1kUFv1DAQhS3UipbSK0fkI5ddbCdOnBNCFQWkol7gbDn2pJ1VYgfb2aqc-8PxdpeqIHGwPJK_997I7xU58sEDIW84W3MumvfJonHbtXEbUfP2BTkVVStXQtbq6Nl8Qs5T2jDGeN00kncvyUmlWMerjp2Sh28wGZ_RA0V_iz3mRG2IGa0ZaZojGIf-hjqYw2gi_jIZg6fGO4rTHMMWEvWwlMEkuxSCDou3j8wQxjHc7cQRZsiYcQs0R7NMxcPSPhr0JXOzxPvX5HgwY4Lzw31Gflx--n7xZXV1_fnrxcerla06nldKQCukkr1kXArZOls3zglQzjowTdcOfd9Yw3rrqt2RSjVKFlUt26GxvDojH_a-89JP4Cz4ss-o54iTifc6GNR_v3i81TdhqzlTtWoFKw7vDg4x_FwgZT1hsjCOxkNYkhYdE52sZSUK-vZ52FPKn78vwHoP2BhSijA8IZzpXb96368-9FsE9T8Ci_mxkLIsjv-T_QY5irKK
CitedBy_id crossref_primary_10_1038_s41582_024_00973_9
crossref_primary_10_1007_s12975_024_01237_w
crossref_primary_10_1017_cjn_2024_38
crossref_primary_10_1186_s12967_024_05916_y
crossref_primary_10_1097_JS9_0000000000001348
crossref_primary_10_4103_RMR_REGENMED_D_24_00001
crossref_primary_10_1007_s40122_024_00668_5
crossref_primary_10_1089_neu_2024_0118
Cites_doi 10.1002/anie.201503312
10.1016/j.neuropharm.2022.109176
10.4085/1062-6050-144-17
10.1186/s12868-015-0147-5
10.1016/j.nbd.2023.106269
10.1093/brain/awp102
10.1089/neu.2018.5844
10.3171/2018.12.JNS181130
10.1186/s13054-019-2711-3
10.1124/jpet.106.117101
10.1093/brain/awab450
10.1016/j.expneurol.2018.04.007
10.1038/jcbfm.2010.191
10.1089/neu.2013.3019
10.1016/j.jneumeth.2011.09.003
10.1016/0304-3940(95)11785-U
10.1124/pr.117.015198
10.1016/j.nbd.2012.06.024
10.1016/S0006-8993(01)02617-8
10.1177/0271678X17734100
10.1371/journal.pbio.3000410
10.1001/jamaneurol.2014.2682
10.1016/S1474-4422(11)70243-5
10.1016/0006-8993(87)90682-2
10.1016/j.neuropharm.2014.04.018
10.1093/brain/aws152
10.1007/s12028-014-0050-4
10.3171/2020.1.JNS192914
10.1016/j.bbr.2017.04.017
10.1089/089771502753754037
10.1212/WNL.0b013e3182886932
10.1016/0013-4694(87)90213-6
10.1016/j.brainresbull.2016.03.013
10.1172/JCI200421227
10.1093/brain/awab457
10.1016/0006-8993(88)90690-7
10.1023/A:1018856020583
10.1161/STROKEAHA.109.549303
10.1002/jcph.980
10.1089/neu.2019.6483
10.1097/00004647-199809000-00007
10.1007/978-3-030-04615-6_16
10.1007/s12028-021-01351-9
10.1001/jamaneurol.2019.4476
10.1016/j.neuroimage.2009.08.009
10.1177/0271678X20915801
10.1523/ENEURO.0070-19.2019
10.1016/j.expneurol.2023.114445
10.1093/brain/awl297
10.1097/HTR.0000000000000628
10.1093/brain/awaa140
10.1159/000102568
10.1016/0014-2999(89)90384-1
10.1038/nrneurol.2010.74
10.1097/PSY.0b013e318244c604
10.1093/brain/117.1.199
10.1177/0271678X16646586
10.1016/0006-8993(87)91652-0
10.3390/ijms222111642
10.1007/s12028-021-01429-4
10.3171/jns.1994.80.2.0291
10.1371/currents.RRN1291
10.1016/j.celrep.2021.109794
10.1093/brain/awq117
10.1007/s007010050491
10.3171/2021.3.JNS204163
10.1093/brain/awu241
10.1089/neu.2009.0961
10.1038/nm.3407
10.1523/JNEUROSCI.0587-16.2016
10.1016/0006-8993(90)90101-G
10.1089/neu.2016.4528
10.1002/gps.4074
10.1093/brain/awx350
10.1073/pnas.1902647116
10.1016/j.neuropharm.2017.09.027
10.1177/0271678X16654496
10.1073/pnas.071582498
10.2119/2008-00050.Beauchamp
10.1038/nm.2333
ContentType Journal Article
Copyright Copyright © 2023 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works. Distributed under a Creative Commons Attribution NonCommercial License 4.0 (CC BY-NC). 2023 The Authors
Copyright_xml – notice: Copyright © 2023 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works. Distributed under a Creative Commons Attribution NonCommercial License 4.0 (CC BY-NC). 2023 The Authors
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7X8
5PM
DOI 10.1126/sciadv.adj2417
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
PubMed Central (Full Participant titles)
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic
CrossRef
MEDLINE
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Sciences (General)
DocumentTitleAlternate Memantine and Cortical Spreading Depolarization
EISSN 2375-2548
ExternalDocumentID PMC10848720
38091390
10_1126_sciadv_adj2417
Genre Randomized Controlled Trial, Veterinary
Research Support, Non-U.S. Gov't
Journal Article
GrantInformation_xml – fundername: ;
  grantid: NDD 168164
– fundername: ;
  grantid: Research Fellowship Grant
– fundername: ;
  grantid: DFG DR 323/10-1
– fundername: ;
  grantid: 488048
– fundername: ;
  grantid: BMBF 01EW2004
GroupedDBID 53G
5VS
AAFWJ
AAYXX
ACGFS
ADAXU
ADBBV
ADPDF
AENVI
AFPKN
ALMA_UNASSIGNED_HOLDINGS
AOIJS
BCGUY
BCNDV
BKF
CITATION
EBS
FRP
GROUPED_DOAJ
GX1
HYE
KQ8
M48
M~E
OK1
OVD
OVEED
RHI
RPM
TEORI
BBORY
CGR
CUY
CVF
ECM
EIF
NPM
7X8
5PM
ID FETCH-LOGICAL-c391t-82e72585b5015257dc46dd2e8dcdea697fbb6ca0bcd3bcd358868582e457f6c13
IEDL.DBID M48
ISSN 2375-2548
IngestDate Thu Aug 21 18:35:27 EDT 2025
Thu Jul 10 23:23:42 EDT 2025
Sat Jun 14 01:30:58 EDT 2025
Tue Jul 01 03:11:55 EDT 2025
Thu Apr 24 22:50:00 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 50
Language English
License This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial license, which permits use, distribution, and reproduction in any medium, so long as the resultant use is not for commercial advantage and provided the original work is properly cited.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c391t-82e72585b5015257dc46dd2e8dcdea697fbb6ca0bcd3bcd358868582e457f6c13
Notes ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Undefined-1
ObjectType-Feature-3
content type line 23
ORCID 0000-0002-8535-0776
0000-0001-7459-2828
0000-0002-7444-2851
0000-0002-8211-7450
0009-0005-3437-5067
0000-0003-4780-8456
0000-0003-3816-6674
OpenAccessLink http://journals.scholarsportal.info/openUrl.xqy?doi=10.1126/sciadv.adj2417
PMID 38091390
PQID 2902954532
PQPubID 23479
ParticipantIDs pubmedcentral_primary_oai_pubmedcentral_nih_gov_10848720
proquest_miscellaneous_2902954532
pubmed_primary_38091390
crossref_primary_10_1126_sciadv_adj2417
crossref_citationtrail_10_1126_sciadv_adj2417
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2023-12-15
PublicationDateYYYYMMDD 2023-12-15
PublicationDate_xml – month: 12
  year: 2023
  text: 2023-12-15
  day: 15
PublicationDecade 2020
PublicationPlace United States
PublicationPlace_xml – name: United States
PublicationTitle Science advances
PublicationTitleAlternate Sci Adv
PublicationYear 2023
Publisher American Association for the Advancement of Science
Publisher_xml – name: American Association for the Advancement of Science
References e_1_3_2_26_2
Mohammad L. M. (e_1_3_2_45_2) 2020; 134
e_1_3_2_49_2
e_1_3_2_28_2
e_1_3_2_41_2
e_1_3_2_64_2
e_1_3_2_87_2
e_1_3_2_20_2
e_1_3_2_43_2
e_1_3_2_62_2
e_1_3_2_85_2
e_1_3_2_22_2
e_1_3_2_68_2
e_1_3_2_24_2
e_1_3_2_66_2
e_1_3_2_60_2
e_1_3_2_83_2
e_1_3_2_81_2
e_1_3_2_9_2
Carlson A. P. (e_1_3_2_39_2) 2018
e_1_3_2_16_2
e_1_3_2_37_2
e_1_3_2_7_2
e_1_3_2_18_2
e_1_3_2_54_2
e_1_3_2_75_2
e_1_3_2_10_2
e_1_3_2_31_2
e_1_3_2_52_2
e_1_3_2_73_2
e_1_3_2_5_2
e_1_3_2_12_2
e_1_3_2_33_2
e_1_3_2_58_2
e_1_3_2_79_2
e_1_3_2_3_2
e_1_3_2_14_2
e_1_3_2_35_2
e_1_3_2_56_2
e_1_3_2_77_2
Thomas S. J. (e_1_3_2_65_2) 2009; 4
e_1_3_2_50_2
e_1_3_2_71_2
Willis C. (e_1_3_2_67_2) 2004; 2003
e_1_3_2_27_2
e_1_3_2_48_2
e_1_3_2_29_2
e_1_3_2_40_2
e_1_3_2_86_2
e_1_3_2_21_2
e_1_3_2_42_2
e_1_3_2_63_2
e_1_3_2_84_2
e_1_3_2_23_2
e_1_3_2_44_2
e_1_3_2_69_2
e_1_3_2_25_2
e_1_3_2_46_2
Kornhuber J. (e_1_3_2_47_2) 1994; 43
e_1_3_2_82_2
e_1_3_2_80_2
e_1_3_2_15_2
e_1_3_2_38_2
e_1_3_2_8_2
e_1_3_2_17_2
e_1_3_2_59_2
e_1_3_2_6_2
e_1_3_2_19_2
e_1_3_2_30_2
e_1_3_2_53_2
e_1_3_2_76_2
e_1_3_2_32_2
e_1_3_2_51_2
e_1_3_2_74_2
e_1_3_2_11_2
e_1_3_2_34_2
e_1_3_2_57_2
Kafi H. (e_1_3_2_61_2) 2014; 13
e_1_3_2_4_2
e_1_3_2_13_2
e_1_3_2_36_2
e_1_3_2_55_2
e_1_3_2_78_2
e_1_3_2_2_2
e_1_3_2_72_2
e_1_3_2_70_2
References_xml – ident: e_1_3_2_85_2
  doi: 10.1002/anie.201503312
– ident: e_1_3_2_32_2
  doi: 10.1016/j.neuropharm.2022.109176
– ident: e_1_3_2_17_2
  doi: 10.4085/1062-6050-144-17
– ident: e_1_3_2_27_2
  doi: 10.1186/s12868-015-0147-5
– ident: e_1_3_2_71_2
  doi: 10.1016/j.nbd.2023.106269
– ident: e_1_3_2_24_2
  doi: 10.1093/brain/awp102
– ident: e_1_3_2_15_2
  doi: 10.1089/neu.2018.5844
– ident: e_1_3_2_28_2
  doi: 10.3171/2018.12.JNS181130
– ident: e_1_3_2_40_2
  doi: 10.1186/s13054-019-2711-3
– ident: e_1_3_2_50_2
  doi: 10.1124/jpet.106.117101
– volume: 13
  start-page: 591
  year: 2014
  ident: e_1_3_2_61_2
  article-title: Study of the neuroprotective effects of memantine in patients with mild to moderate ischemic stroke
  publication-title: Iran. J. Pharm. Res.
– ident: e_1_3_2_6_2
  doi: 10.1093/brain/awab450
– ident: e_1_3_2_30_2
  doi: 10.1016/j.expneurol.2018.04.007
– ident: e_1_3_2_5_2
  doi: 10.1038/jcbfm.2010.191
– ident: e_1_3_2_2_2
  doi: 10.1089/neu.2013.3019
– ident: e_1_3_2_83_2
  doi: 10.1016/j.jneumeth.2011.09.003
– ident: e_1_3_2_64_2
  doi: 10.1016/0304-3940(95)11785-U
– ident: e_1_3_2_43_2
  doi: 10.1124/pr.117.015198
– ident: e_1_3_2_9_2
  doi: 10.1016/j.nbd.2012.06.024
– ident: e_1_3_2_48_2
  doi: 10.1016/S0006-8993(01)02617-8
– volume: 2003
  start-page: CD003986
  year: 2004
  ident: e_1_3_2_67_2
  article-title: Excitatory amino acid inhibitors for traumatic brain injury
  publication-title: Cochrane Database Syst. Rev.
– ident: e_1_3_2_55_2
  doi: 10.1177/0271678X17734100
– ident: e_1_3_2_81_2
  doi: 10.1371/journal.pbio.3000410
– ident: e_1_3_2_76_2
  doi: 10.1001/jamaneurol.2014.2682
– ident: e_1_3_2_12_2
  doi: 10.1016/S1474-4422(11)70243-5
– ident: e_1_3_2_20_2
  doi: 10.1016/0006-8993(87)90682-2
– ident: e_1_3_2_31_2
  doi: 10.1016/j.neuropharm.2014.04.018
– ident: e_1_3_2_41_2
  doi: 10.1093/brain/aws152
– ident: e_1_3_2_42_2
  doi: 10.1007/s12028-014-0050-4
– volume: 134
  start-page: 1294
  year: 2020
  ident: e_1_3_2_45_2
  article-title: Spreading depolarization may represent a novel mechanism for delayed fluctuating neurological deficit after chronic subdural hematoma evacuation
  publication-title: J. Neurosurg.
  doi: 10.3171/2020.1.JNS192914
– ident: e_1_3_2_60_2
  doi: 10.1016/j.bbr.2017.04.017
– ident: e_1_3_2_3_2
  doi: 10.1089/089771502753754037
– ident: e_1_3_2_26_2
  doi: 10.1212/WNL.0b013e3182886932
– ident: e_1_3_2_37_2
  doi: 10.1016/0013-4694(87)90213-6
– volume: 43
  start-page: 91
  year: 1994
  ident: e_1_3_2_47_2
  article-title: Amantadine and memantine are NMDA receptor antagonists with neuroprotective properties
  publication-title: J. Neural Transm. Suppl.
– ident: e_1_3_2_58_2
  doi: 10.1016/j.brainresbull.2016.03.013
– ident: e_1_3_2_73_2
  doi: 10.1172/JCI200421227
– ident: e_1_3_2_14_2
  doi: 10.1093/brain/awab457
– ident: e_1_3_2_35_2
  doi: 10.1016/0006-8993(88)90690-7
– ident: e_1_3_2_62_2
  doi: 10.1023/A:1018856020583
– ident: e_1_3_2_38_2
  doi: 10.1161/STROKEAHA.109.549303
– ident: e_1_3_2_52_2
  doi: 10.1002/jcph.980
– ident: e_1_3_2_78_2
  doi: 10.1089/neu.2019.6483
– start-page: 1
  year: 2018
  ident: e_1_3_2_39_2
  article-title: Spreading depolarization in acute brain injury inhibited by ketamine: A prospective, randomized, multiple crossover trial
  publication-title: J. Neurosurg.
– ident: e_1_3_2_23_2
  doi: 10.1097/00004647-199809000-00007
– ident: e_1_3_2_34_2
  doi: 10.1007/978-3-030-04615-6_16
– ident: e_1_3_2_51_2
  doi: 10.1007/s12028-021-01351-9
– ident: e_1_3_2_7_2
  doi: 10.1001/jamaneurol.2019.4476
– ident: e_1_3_2_84_2
  doi: 10.1016/j.neuroimage.2009.08.009
– ident: e_1_3_2_8_2
  doi: 10.1177/0271678X20915801
– ident: e_1_3_2_16_2
  doi: 10.1523/ENEURO.0070-19.2019
– ident: e_1_3_2_74_2
  doi: 10.1016/j.expneurol.2023.114445
– ident: e_1_3_2_10_2
  doi: 10.1093/brain/awl297
– volume: 4
  start-page: 367
  year: 2009
  ident: e_1_3_2_65_2
  article-title: Memantine: A review of studies into its safety and efficacy in treating Alzheimer’s disease and other dementias
  publication-title: Clin. Interv. Aging
– ident: e_1_3_2_72_2
  doi: 10.1097/HTR.0000000000000628
– ident: e_1_3_2_77_2
  doi: 10.1093/brain/awaa140
– ident: e_1_3_2_46_2
  doi: 10.1159/000102568
– ident: e_1_3_2_63_2
  doi: 10.1016/0014-2999(89)90384-1
– ident: e_1_3_2_79_2
  doi: 10.1038/nrneurol.2010.74
– ident: e_1_3_2_18_2
  doi: 10.1097/PSY.0b013e318244c604
– ident: e_1_3_2_22_2
  doi: 10.1093/brain/117.1.199
– ident: e_1_3_2_33_2
  doi: 10.1177/0271678X16646586
– ident: e_1_3_2_36_2
  doi: 10.1016/0006-8993(87)91652-0
– ident: e_1_3_2_87_2
  doi: 10.3390/ijms222111642
– ident: e_1_3_2_44_2
  doi: 10.1007/s12028-021-01429-4
– ident: e_1_3_2_82_2
  doi: 10.3171/jns.1994.80.2.0291
– ident: e_1_3_2_66_2
  doi: 10.1371/currents.RRN1291
– ident: e_1_3_2_53_2
  doi: 10.1016/j.celrep.2021.109794
– ident: e_1_3_2_11_2
  doi: 10.1093/brain/awq117
– ident: e_1_3_2_49_2
  doi: 10.1007/s007010050491
– ident: e_1_3_2_69_2
  doi: 10.3171/2021.3.JNS204163
– ident: e_1_3_2_25_2
  doi: 10.1093/brain/awu241
– ident: e_1_3_2_13_2
  doi: 10.1089/neu.2009.0961
– ident: e_1_3_2_80_2
  doi: 10.1038/nm.3407
– ident: e_1_3_2_57_2
  doi: 10.1523/JNEUROSCI.0587-16.2016
– ident: e_1_3_2_29_2
  doi: 10.1016/0006-8993(90)90101-G
– ident: e_1_3_2_59_2
  doi: 10.1089/neu.2016.4528
– ident: e_1_3_2_54_2
  doi: 10.1002/gps.4074
– ident: e_1_3_2_75_2
  doi: 10.1093/brain/awx350
– ident: e_1_3_2_56_2
  doi: 10.1073/pnas.1902647116
– ident: e_1_3_2_86_2
– ident: e_1_3_2_19_2
  doi: 10.1016/j.neuropharm.2017.09.027
– ident: e_1_3_2_70_2
  doi: 10.1177/0271678X16654496
– ident: e_1_3_2_21_2
  doi: 10.1073/pnas.071582498
– ident: e_1_3_2_68_2
  doi: 10.2119/2008-00050.Beauchamp
– ident: e_1_3_2_4_2
  doi: 10.1038/nm.2333
SSID ssj0001466519
Score 2.3221593
Snippet Cortical spreading depolarization (CSD) is a promising target for neuroprotective therapy in traumatic brain injury (TBI). We explored the effect of NMDA...
SourceID pubmedcentral
proquest
pubmed
crossref
SourceType Open Access Repository
Aggregation Database
Index Database
Enrichment Source
StartPage eadj2417
SubjectTerms Animals
Brain - metabolism
Brain Injuries, Traumatic - drug therapy
Electrocorticography
Memantine - pharmacology
Neuroscience
Rats
Receptors, N-Methyl-D-Aspartate - metabolism
SciAdv r-articles
Title Memantine inhibits cortical spreading depolarization and improves neurovascular function following repetitive traumatic brain injury
URI https://www.ncbi.nlm.nih.gov/pubmed/38091390
https://www.proquest.com/docview/2902954532
https://pubmed.ncbi.nlm.nih.gov/PMC10848720
Volume 9
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1Lb9QwELagXLiglucCrYyEBBxSOU78yAFVCFEqpOXESnuL_Iqaqs0um90C9_7wzjjepUtB4pDkkIljeTLxzHj8fYS8Dk3RVCaoLJSyyBCfJLOmKcHcmfaVFY2IPGTjr_JkUn6Ziunv-qc0gP1fQzvkk5oszg9_fv91BAb__sYGGOMvD40_g-lI3SX38IJsBuPk6sd8SymliDwfvFAig7hIJwzH201sz1G3HM8_6ydvTEjHu-RB8iTph0H1e-RO6B6SvWSrPX2bAKXfPSJX43BhkBEi0LY7bW277CkEnTGLTfv5Yqijpx58cRiMtDGTms7TNqYcoLUIe7muWqU4GUaZBr6i2Q98eBHmuF8N_p0UOruKQLDUIv8EvPMMFPeYTI4_fft4kiX2hcwVVb7MNA-KQzBhBUOOJOVdKb3nQXvng5GVaqyVzjDrfIGH0Bqx7HkohWqky4snZKebdeEZoZYJrvKqNEz40jmrjVWmglAlINoaK0YkW4937RI0OTJknNcxROGyHvRTJ_2MyJuN_HwA5fin5Ku1-mqwG1wMMV2YrfqaVwyXOEXBR-TpoM5NW4WOaKlsRPSWojcCiMm9fadrTyM2d478BIqz5__dxRfkPlLYY4lMLl6SneViFfbB0Vnag5gggPPnaX4Qv-ZrWdcHHA
linkProvider Scholars Portal
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Memantine+inhibits+cortical+spreading+depolarization+and+improves+neurovascular+function+following+repetitive+traumatic+brain+injury&rft.jtitle=Science+advances&rft.au=MacLean%2C+Mark+A.&rft.au=Muradov%2C+Jamil+H.&rft.au=Greene%2C+Ryan&rft.au=Van+Hameren%2C+Gerben&rft.date=2023-12-15&rft.issn=2375-2548&rft.eissn=2375-2548&rft.volume=9&rft.issue=50&rft_id=info:doi/10.1126%2Fsciadv.adj2417&rft.externalDBID=n%2Fa&rft.externalDocID=10_1126_sciadv_adj2417
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2375-2548&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2375-2548&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2375-2548&client=summon